iCare, a subsidiary of Revenio Group, announced it will commercially launch the latest version of its iCare MAIA microperimeter in the first quarter of 2025. 

According to a company press release, the new iCare MAIA features a renewed hardware platform with fully automated operations and a 15’’ multi-touch display, along with an intuitive user interface. In addition, the auto-alignment capability feature keeps the device aligned with the eye under exam, compensating for head movements throughout the test. Also, the structure-function correlation of the device has also been improved with the introduction of the 60° TrueColor field of view.

Other features of the new iCare MAIA include an onboard grid editor that allows for the creation of customized test patterns, ensuring higher flexibility for the execution of custom protocols for patient-specific testing. The new device can also import data from the previous model and use it as a reference for follow-up examination allowing full continuity with clinical historical data, iCare said. 

According to the company, clinical validation indicates full interchangeability with previous MAIA generation, with equivalent sensitivity results in mesopic testing.

Additionally, iCare stated that the update represents a significant step in its growth and innovation strategy, aimed at better meeting market diagnostic needs, particularly within the ophthalmic research segment focusing on geographic atrophy therapies development.